Onco Wiki / Indication
Primary Mediastinal (Thymic) Large B-Cell Lymphoma · line 1 · Dose-adjusted EPOCH + rituximab (DA-EPOCH-R)
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
Contenu clinique provisoire : il ne s'agit pas d'une ordonnance. Un oncologue doit vérifier les sources originales, l'applicabilité et le statut de révision.
Source YAML: dossier complet
Notes
STUB — pending Clinical Co-Lead approval. End-of-induction PET-CT визначає чи потрібна consolidation RT (Deauville 4-5 → RT; 1-3 → no RT).
Evidence for specific statements
These citations cover only the statements and scopes shown. They do not establish clinical approval of this record.
The prospective single-group NCI cohort included 51 untreated PMBCL patients. Its reported 93% endpoint is event-free survival during a median five years of follow-up; it must not be labelled progression-free survival or an individual probability of cure.
Endpoint terminology in the cited NCI cohort only; not verification of other response/survival estimates, RT rules, treatment selection or the entire indication.
SRC-DUNLEAVY-PMBCL-DAEPOCH-2013
Dunleavy 2013 primary abstract: Methods and Results.
Utilisé par
Algorithmes
ALGO-PMBCL-1L - ALGO-PMBCL-1L